Amlevo TM 2.5 Tablet: Each tablet contains Levamlodipine Besylate INN equivalent to 2.5 mg Levamlodipine.
Amlevo TM 5 Tablet: Each tablet contains Levamlodipine Besylate INN equivalent to 5 mg Levamlodipine.
Amlevo TM is a preparation of Levamlodipine. Levamlodipine is a calcium antagonist (calcium channel blocker) of the dihydropyridine group and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle. The mechanism of the antihypertensive action of Levamlodipine is due to a direct relaxant effect on vascular smooth muscle.
Adult: Starting dose 2.5 mg once daily with maximum dose 5 mg once daily.
Levamlodipine has been safely administered with thiazide diuretics, beta-adrenoceptor blocking drugs, angiotensin-converting enzyme inhibitors, long-acting nitrates, sublingual glyceryl trinitrate, non-steroidal anti-inflammatory drugs, antibiotics and oral hypoglycaemic agents. Co-administration of Levamlodipine with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers. In healthy volunteers, co-administration of Levamlodipine did not significantly alter the effect of warfarin on prothrombin time. The introduction of Levamlodipine is not likely to result in the need for modification of an established warfarin regimen. In vitro data from studies with human plasma indicates that Levamlodipine has no effect on protein binding of digoxin, phenytoin, warfarin or indomethacin.
Use during pregnancy and lactation: Although some dihydropyridine compounds have been found to be teratogenic in animals, data in the rat and rabbit for Levamlodipine provide no evidence for a teratogenic effect.
There is, however no clinical experience with Levamlodipine in pregnancy or lactation.
To be dispensed only by the prescription of a registered physician.
Store at or below 25°C temperature. Keep away from light and wet place. Keep out of reach of children.